Coreg (carvedilol) for MI patients with decreased left ventricular function
July 2003
Glaxo is now promoting Coreg (carvedilol) for MI patients with decreased left ventricular function.
Coreg is the first beta-blocker APPROVED specifically for these patients. It reduces mortality by about 23%.
Some reps will say that Coreg is better than the older beta-blockers...metoprolol, atenolol, propranolol, etc.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote